Janne Jokinen

Dr. Janne Jokinen


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2007 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
JJJanne Jokinen
Janne Jokinen
MHMikko J. Hippeläinen
Mikko J. Hippeläinen
OPOtto A. Pitkänen
Otto A. Pitkänen
JHJuha E.K. Hartikainen
Juha E.K. Hartikainen

1 June 2009 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
JJJanne Jokinen
Janne Jokinen
ATAnu K. Turpeinen
Anu K. Turpeinen
OPOtto Pitkänen
Otto Pitkänen
MHMikko J. Hippeläinen
Mikko J. Hippeläinen
JHJuha E.K. Hartikainen
Juha E.K. Hartikainen

1 June 2011 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
JJJanne Jokinen
Janne Jokinen
KWKalervo Werkkala
Kalervo Werkkala
TVTiina Vainikka
Tiina Vainikka
TPTarja Peräkylä
Tarja Peräkylä
JSJarmo Simpanen
Jarmo Simpanen
LILeo Ihlberg
Leo Ihlberg
Transit-time flow measurement (TTFM) is the most widely used method for intra-operative graft quality control in coronary artery bypass surgery. Although it may provide the opportunity for the surgeon to promptly revise the graft before the patient is discharged from the operating room, controlled clinical data on the ultimate usefulness of the TTFM are scarce. Clear cut-off values for when to revise grafts have not been set. A total of 204 consecutive grafts (left internal mammary artery (n=46), vein graft (n=155), and radial artery (n=3)) underwent TTFM in 75 elective coronary artery bypass grafting (CABG) patients. The following parameters were recorded: mean graft flow (MGF), pulsatility index (PI), and insufficiency ratio (IR). After a mean follow-up of 199 ± 42 days, coronary angiography was performed for assessment of graft patency. A total of 166 grafts were found to be patent (85%), and 29 (15%) were completely occluded. The median and interquartile range (IQR) of MGF for the occluded grafts at the time of surgery was 38 ml min(-1) (IQR, 2549 ml min(-1)) and for the patent grafts 45 ml min(-1) (IQR, 31-71 ml min(-1); p=ns]. The corresponding PI values were 3.3 (IQR, 2.8-5.0) and 2.2 (IQR, 1.7-3.2; p=0.003), and the IR values were 1.6 (IQR, 0.6-6.1) and 0.2 (IQR, 0-2.2; p=0.03). By receiver operating characteristic (ROC) analysis, the highest sensitivity (72%) and specificity (70%) were associated with a PI value>3.0. However, 49 out of 70 such grafts (70%) were found to be patent. Furthermore, 10 out of 16 (63%) grafts, that had a combination of low flow (MGF3.0), were patent at control angiography. TTFM predicts graft failure within the 6 months after CABG. However, specific cut-off recommendations for when to revise a graft cannot be set on the basis of TTFM. The cut-off values suggested in the literature lead to unnecessary graft revisions in the majority of cases, and, on the other hand, many technical defects probably remain unnoticed. Better methods to assess the quality of coronary artery bypass grafts are needed.

1 May 2016 in Advances in Wound Care
Verified
Journal Article
Open access
JJJanne Jokinen
Janne Jokinen
ASArno Sipponen
Arno Sipponen
Significance: The treatment of chronic wounds results in an enormous drain on healthcare resources in terms of workload, costs, frustration, and impaired quality of life, and it presents a clinical challenge for physicians worldwide. Effective local treatment of a chronic wound has an important role, particularly in patients who are—because of their poor general condition, diminished life expectancy, or unacceptable operative risk—outside of surgical treatment. Recent Advances: Since 2002, our multidisciplinary research group has investigated the properties of Norway spruce ( Picea abies ) resin in wound healing and its therapeutic applications in wound care. Resin is a complex mixture of resin acids ( e.g., abietic, neoabietic, dehydroabietic, pimaric, isopimaric, levopimaric, sandrakopimaric, and palustric acids) and lignans ( e.g., pino-, larici-, matairesinol, and p-hydroxycinnamic acid) having substantial antimicrobial, wound-healing, and skin regeneration enhancing properties. Critical Issues: The cornerstone in successful wound care is an efficient causal treatment of the underlying co-morbidities, for example, diabetes, malnutrition, vascular- or certain systemic diseases. However, definitive diagnosis and specific therapy of a chronic wound is often difficult, because the etiology is practically always multi-factorial, and in the chronic phase, confounding factors such as infections invariably impede wound healing. Future Directions: To study the exact molecular mechanism of actions by which resin promotes cellular regeneration and epithelialization during the wound-healing process. To investigate potential antimicrobial properties of resin against the most ominous multidrug-resistant beta-lactamase (including carbapenemases and metallo-β-lactamases) producing bacteria, and to individualize those pharmacologically active compounds which are responsible for the antimicrobial activity of resin.

1 May 2008 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
ASA. Sipponen
A. Sipponen
JJJanne Jokinen
Janne Jokinen
PSP. Sipponen
P. Sipponen
APA. Papp
A. Papp
SSS. Sarna
S. Sarna
JLJ. Lohi
J. Lohi

1 November 2012 in The American Journal of Pathology
Verified
Journal Article
Closed access
RKRainer Krebs
Rainer Krebs
JTJussi M. Tikkanen
Jussi M. Tikkanen
JRJussi O. Ropponen
Jussi O. Ropponen
Michael JeltschMichael Jeltsch
Michael Jeltsch
JJJanne Jokinen
Janne Jokinen
KLKarl Lemström
Karl Lemström